Last reviewed · How we verify
Ribavarin
At a glance
| Generic name | Ribavarin |
|---|---|
| Also known as | Copegus, Rebetol |
| Sponsor | Charles University, Czech Republic |
| Target | Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
- Chronic hepatitis C
- Compensated cirrhosis
- Respiratory syncytial virus infection
Common side effects
Key clinical trials
- Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection (NA)
- Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients (Phase 4)
- An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients (Phase 2)
- A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Pr (Phase 3)
- A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects (Phase 3)
- Airway Intervention Registry (AIR) Extension: Recurrent Respiratory Papillomatosis (N/A)
- Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Par (Phase 4)
- A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |